Zurück
Keine Kauf Empfehlung!!
Wen nicht fähig ist, selber eine Meinung zu bilden und eine Entscheidung zu treffen, darf nicht zur Börse.
Wen nicht fähig ist, selber eine Meinung zu bilden und eine Entscheidung zu treffen, darf nicht zur Börse.
Top-News
CEL-SCI CORP. DL-01 (WKN: 871006)
Beiträge: 95
Zugriffe: 14.109 / Heute: 3
Zugriffe: 14.109 / Heute: 3
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +75,36%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +59,57%
Amundi Japan TOPIX II UCITS ETF - EUR Hedeged Dist
Perf. 12M: +37,65%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +37,47%
wieso geht die auf einmal so ab? Kopfschüttel, weiß einer mehr??
... eine Akazie im Depot gehabt, die so miserabel abstürzte und keinerlei Regung zeigt.
Ist die schon tot?
Wer hat eine Ahnung was aus dieser offensichtlichen Depotleiche werden, oder nicht werden kann?
Gruss
Ist die schon tot?
Wer hat eine Ahnung was aus dieser offensichtlichen Depotleiche werden, oder nicht werden kann?
Gruss
abwarten. Was anderes bleibt einem nicht übrig; das wird schon.
Meine Meinung, keine Empfehlung.
Gelöschter Beitrag.
Einblenden
»
#80 
Neueste Nachricht im Biomedreports!
biomedreports.com/articles/most-popular/...cs-nasdaq-agen.html
Schon 10% hoch und gutes Volumen.
Hier dürfte bald die Post abgehen!
Viel Erfolg!
biomedreports.com/articles/most-popular/...cs-nasdaq-agen.html
Schon 10% hoch und gutes Volumen.
Hier dürfte bald die Post abgehen!
Viel Erfolg!
gut beobachtet
nun bestätigt
weißt du mehr
mfg
www.mysmartrend.com/news-briefs/...ullish-engulfing-pattern-ce
und noch aktuelle news
www.businesswire.com/portal/site/home/...06452&newsLang=en
nun bestätigt
weißt du mehr
mfg
www.mysmartrend.com/news-briefs/...ullish-engulfing-pattern-ce
und noch aktuelle news
www.businesswire.com/portal/site/home/...06452&newsLang=en
Jugendkriminalität ist der Dank unserer Jugend, mehr und mehr ihrer Kindheit beraubt zu werden.
An sich ist die Celi ein verlässlicher Wert, da nicht otc gehandelt. Liegt wahrscheinlich ein bischen daran, aber wenn endlich news zu deren FDA Freigaben kommen, wird hier die Post dermaßen abgehen, dass ein hinterherkommen nur mit deutlichen Aufschlägen möglich sein wird.
Meine Meinung, keine Empfehlung.
www.businesswire.com/portal/site/home/...05361&newsLang=en
Jugendkriminalität ist der Dank unserer Jugend, mehr und mehr ihrer Kindheit beraubt zu werden.
www.cel-sci.com/letter_to_shareholders.html
13.09.2010 15:45
www.finanznachrichten.de/...ii-clinical-trial-of-multi-004.htm
CEL-SCI Corporation Receives Approval from North Mississippi Health Services' Institutional Review Board to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
CEL-SCI Corporation (NYSE AMEX: CVM) announced today it has received approval from the North Mississippi Health Services ("North Mississippi") Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.
CEL-SCI's Phase III clinical trial is an open-label, randomized, multi-center study designed to determine if Multikine administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Chemo radiotherapy) in subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased overall rate of survival versus the subjects treated with standard of care only. North Mississippi is the first site in the United States to approve enrollment of subjects. CEL-SCI's trial will be conducted in nine countries and is expected to be the largest clinical study of head and neck cancer ever conducted. It will also be the first trial in which immunotherapy will be administered before any other traditional means of care are attempted. CEL-SCI plans to announce additional site approvals and country approvals as they become known.
Phase II clinical trials of Multikine demonstrated the product was safe and well-tolerated and eliminated tumors in 12% of the subjects less than a month into treatment. The Multikine treatment regimen was also shown to kill, on average, about half of the cancer cells in the subjects' tumors before the start of standard therapy. Follow-up studies of subjects enrolled in Phase II trials showed a 33% improvement in the survival rate of those treated with Multikine at a median of three and a half years following surgery. The U.S. Food and Drug Administration gave clearance for a Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck.
About North Mississippi Health Services
North Mississippi Health Services (NMHS) is a diversified regional health care organization, which serves 24 counties in north Mississippi and northwest Alabama from headquarters in Tupelo, Mississippi. The NMHS organization covers a broad range of acute diagnostic and therapeutic services, offered through North Mississippi Medical Center in Tupelo; a community hospital system with locations in Eupora, Iuka, Pontotoc, West Point, Miss. and Hamilton, Alabama, North Mississippi Medical Clinics, a regional network of more than 30 primary and specialty clinics; and nursing homes. NMHS has an IRB that meets monthly. The NMHS IRB members include doctors, nurses, pharmacists, social workers, a lawyer, risk manager, and community members. This group reviews the science and ethics of the research. Their objective is to assess the risks and benefits to subjects involved in the study. The NMHS IRB has the authority to approve, require modification to, or disapprove all research activities that involve an NMHS investigator, facility, or patient group. Following initial approval, the IRB conducts periodic reviews of such research. In most instances, in order to approve research, an IRB must determine that specified criteria have been satisfied. Among these criteria, an IRB must determine that, when appropriate, the research protocol includes "adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data."
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine. In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33 percent at a median of three and a half years following surgery. A pivotal Phase III clinical trial with Multikine in head and neck cancer is expected to start in the second half of 2010.
CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
Contacts:
CEL-SCI Corporation
Gavin de Windt, 703-506-9460
© 2010 Business Wire
www.finanznachrichten.de/...ii-clinical-trial-of-multi-004.htm
CEL-SCI Corporation Receives Approval from North Mississippi Health Services' Institutional Review Board to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
CEL-SCI Corporation (NYSE AMEX: CVM) announced today it has received approval from the North Mississippi Health Services ("North Mississippi") Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.
CEL-SCI's Phase III clinical trial is an open-label, randomized, multi-center study designed to determine if Multikine administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Chemo radiotherapy) in subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased overall rate of survival versus the subjects treated with standard of care only. North Mississippi is the first site in the United States to approve enrollment of subjects. CEL-SCI's trial will be conducted in nine countries and is expected to be the largest clinical study of head and neck cancer ever conducted. It will also be the first trial in which immunotherapy will be administered before any other traditional means of care are attempted. CEL-SCI plans to announce additional site approvals and country approvals as they become known.
Phase II clinical trials of Multikine demonstrated the product was safe and well-tolerated and eliminated tumors in 12% of the subjects less than a month into treatment. The Multikine treatment regimen was also shown to kill, on average, about half of the cancer cells in the subjects' tumors before the start of standard therapy. Follow-up studies of subjects enrolled in Phase II trials showed a 33% improvement in the survival rate of those treated with Multikine at a median of three and a half years following surgery. The U.S. Food and Drug Administration gave clearance for a Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck.
About North Mississippi Health Services
North Mississippi Health Services (NMHS) is a diversified regional health care organization, which serves 24 counties in north Mississippi and northwest Alabama from headquarters in Tupelo, Mississippi. The NMHS organization covers a broad range of acute diagnostic and therapeutic services, offered through North Mississippi Medical Center in Tupelo; a community hospital system with locations in Eupora, Iuka, Pontotoc, West Point, Miss. and Hamilton, Alabama, North Mississippi Medical Clinics, a regional network of more than 30 primary and specialty clinics; and nursing homes. NMHS has an IRB that meets monthly. The NMHS IRB members include doctors, nurses, pharmacists, social workers, a lawyer, risk manager, and community members. This group reviews the science and ethics of the research. Their objective is to assess the risks and benefits to subjects involved in the study. The NMHS IRB has the authority to approve, require modification to, or disapprove all research activities that involve an NMHS investigator, facility, or patient group. Following initial approval, the IRB conducts periodic reviews of such research. In most instances, in order to approve research, an IRB must determine that specified criteria have been satisfied. Among these criteria, an IRB must determine that, when appropriate, the research protocol includes "adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data."
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine. In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33 percent at a median of three and a half years following surgery. A pivotal Phase III clinical trial with Multikine in head and neck cancer is expected to start in the second half of 2010.
CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
Contacts:
CEL-SCI Corporation
Gavin de Windt, 703-506-9460
© 2010 Business Wire
CEL-SCI Corporation Receives Approval from North Mississippi Health Services' Institutional Review Board to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
www.finanznachrichten.de/...ii-clinical-trial-of-multi-004.htm
www.finanznachrichten.de/...ii-clinical-trial-of-multi-004.htm
Keine Kauf-Empfehlung!!
Wer nicht fähig ist, selber eine Meinung zu bilden und eine Entscheidung zu treffen, darf nicht zur Börse.
Wer nicht fähig ist, selber eine Meinung zu bilden und eine Entscheidung zu treffen, darf nicht zur Börse.
Schon über 10%.
Ich kann nur keine news finden.
Weiss jemand hier mehr?
Ich kann nur keine news finden.
Weiss jemand hier mehr?
... hatte dieses Ding mal als Empfehlung und so hatte ich vor ca. 8 Monaten eine kleinere Position aufgestellt. Die ist seitdem 65% im Minus.
Wäre ja wirklich erfreulich, wenn hier mal was gehen sollte.
Es geschehen ja vielleicht wirklich noch Zeichen und Wunder und der Aktionär hat sich mal nicht geirrt.
Gruss
Wäre ja wirklich erfreulich, wenn hier mal was gehen sollte.
Es geschehen ja vielleicht wirklich noch Zeichen und Wunder und der Aktionär hat sich mal nicht geirrt.
Gruss
de.www.smallcapnetwork.com/...o/s/article/view/p/mid/1/id/867/
CEL-SCI CORPORATION RECEIVES RUSSIAN FEDERATION ETHICAL COUNCIL APPROVAL FOR MULTIKINE PHASE III CLINICAL TRIAL IN HEAD AND NECK CANCER
Vienna, VA, September 27, 2010 -- CEL-SCI Corporation (NYSE AMEX: CVM)announced today it has received approval from the Ethical Council Affiliated with the Ministry of Healthcare and Social Development of the Russian Federation ("Ethical Council") for the Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. CEL-SCI expects to have three clinical centers in Russia, out of an expected forty-eight clinical centers world-wide. Head and neck cancer is a major cancer in Russia.
CEL-SCI's Phase III clinical trial is an open-label, randomized, multi-center study designed to determine if Multikine administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Chemo radiotherapy) in subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased overall rate of survival versus the subjects treated with standard of care only. North Mississippi Health Services was the first site in the United States to approve enrollment of subjects.
CEL-SCI's trial will be conducted in nine countries and is expected to be the largest clinical study of head and neck cancer ever conducted. It will also be the first trial in which immunotherapy will be administered before any other traditional means of care are attempted.
Phase II clinical trials of Multikine demonstrated the product was safe and well-tolerated and eliminated tumors in 12% of the subjects less than a month into treatment. The Multikine treatment regimen was also shown to kill, on average, about half of the cancer cells in the subjects' tumors before the start of standard therapy. Follow-up studies of subjects enrolled in Phase II trials showed a 33% improvement in the survival rate of those treated with Multikine at a median of three and a half years following surgery. The U.S. Food and Drug Administration gave clearance for a Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck.
www.cel-sci.com
Vienna, VA, September 27, 2010 -- CEL-SCI Corporation (NYSE AMEX: CVM)announced today it has received approval from the Ethical Council Affiliated with the Ministry of Healthcare and Social Development of the Russian Federation ("Ethical Council") for the Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. CEL-SCI expects to have three clinical centers in Russia, out of an expected forty-eight clinical centers world-wide. Head and neck cancer is a major cancer in Russia.
CEL-SCI's Phase III clinical trial is an open-label, randomized, multi-center study designed to determine if Multikine administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Chemo radiotherapy) in subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased overall rate of survival versus the subjects treated with standard of care only. North Mississippi Health Services was the first site in the United States to approve enrollment of subjects.
CEL-SCI's trial will be conducted in nine countries and is expected to be the largest clinical study of head and neck cancer ever conducted. It will also be the first trial in which immunotherapy will be administered before any other traditional means of care are attempted.
Phase II clinical trials of Multikine demonstrated the product was safe and well-tolerated and eliminated tumors in 12% of the subjects less than a month into treatment. The Multikine treatment regimen was also shown to kill, on average, about half of the cancer cells in the subjects' tumors before the start of standard therapy. Follow-up studies of subjects enrolled in Phase II trials showed a 33% improvement in the survival rate of those treated with Multikine at a median of three and a half years following surgery. The U.S. Food and Drug Administration gave clearance for a Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck.
www.cel-sci.com
, da in Taiwan eine Studie zur Multi...wohl in rechten Bahnen verläuft. Die 1 vor dem komma ist näher denn je.
Meine Meinung, keine Empfehlung.
CEL-SCI Corporation Receives Government Approval from Ukraine to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
www.finanznachrichten.de/...ne-in-head-and-neck-cancer-004.htm
www.finanznachrichten.de/...ne-in-head-and-neck-cancer-004.htm
Keine Kauf-Empfehlung!!
Wer nicht fähig ist, selber eine Meinung zu bilden und eine Entscheidung zu treffen, darf nicht zur Börse.
Wer nicht fähig ist, selber eine Meinung zu bilden und eine Entscheidung zu treffen, darf nicht zur Börse.
und daher wird Celi durch die Decke gehen. Schaut mal was in USA passieren wird...Bis morgen ist Celi locker bei 1,50 und wird weiter steigen...
Meine Meinung, keine Empfehlung.
|
Neueste Beiträge aus dem Cel-Sci Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 77 | Ausbrecher nach NEWS(H5N1) | RoulettProfi | PTY7 | 25.04.21 01:41 | |
| 94 | CEL-SCI CORP. DL-01 (WKN: 871006) | Lapismuc | Nodaymla | 29.12.10 14:52 | ||
| 1 | CEL-SCI - kurz vor Phase 3 | Rajiva35 | Rajiva35 | 24.05.06 10:49 |
